# Medimaps Group

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/medimaps-group

- Industry: Software
- Headquarters: Switzerland
- Website: www.medimapsgroup.com
- Total disclosed funding: $20M
- Latest round: Series C (Nov 1, 2021)
- Investors on record: 4

## About

Medimaps Group SA is a Swiss technology company specializing in AI-driven imaging software for assessing bone health and predicting fracture risk, particularly for osteoporosis patients.Founded in 2006 in Switzerland, Medimaps Group SA focuses on the development of imaging solutions for bone health assessment. The company underwent a strategic pivot towards advanced AI applications, establishing itself as a key player in the digital health sector. Most recently, in November 2021, Medimaps Group raised USD 20.00 mn in Series C funding, led by Swisscanto Invest by Zürcher Kantonalbank, with participation from Swiss Entrepreneurs Foundation, Swisscom Ventures, and Verve Ventures. This funding round marked a significant milestone as it represented the total amount raised by the company to date. Medimaps Group has maintained a presence in the healthcare landscape without any known subsidiaries or parent companies.Medimaps Group specializes in advanced deep-tech and AI imaging software designed for the comprehensive assessment of bone microarchitecture and the prediction of fracture risk, particularly in primary and secondary osteoporosis. The flagship product, TBS Osteo, integrates Trabecular Bone Score technology to enhance the evaluation of bone health during DXA bone densitometry scans. This product has been adopted by leading hospitals across the United States, with a significant presence in 16 of the 20 hospitals ranked on the U.S. News Best Hospitals Honor Roll for 2024-2025. TBS Osteo, along with its next-generation software that measures soft tissue thickness, caters to clinicians by providing non-invasive, radiation-free solutions that streamline clinical workflows and improve patient care. Medimaps Group’s technologies are accessible in various markets globally, including the United States, Canada, and Europe, thus addressing the needs of healthcare professionals and patients in regions with high osteoporosis prevalence.Medimaps Group generates revenue primarily through the sale of its advanced imaging software solutions, particularly the TBS Osteo platform, which has been integrated into clinical practices across numerous healthcare facilities. The company operates on a business-to-business model, establishing partnerships with hospitals and healthcare providers, who utilize the software as part of their diagnostic and treatment processes. The transactions typically revolve around licensing agreements or subscription-based models that allow healthcare entities to access the software for patient assessments and ongoing monitoring. Furthermore, the TBS Osteo product benefits from dedicated CPT® codes for Medicare beneficiaries, which aids in reimbursement processes under the PFS and OPPS systems, enhancing financial sustainability for healthcare providers using the technology. As the adoption of their software grows, especially with the increasing recognition of the importance of bone microarchitecture analysis, Medimaps Group is positioned to benefit from a rising demand for its innovative solutions.Following the recent Series C funding round completed in November 2021, Medimaps Group plans to utilize the USD 20.00 mn raised to expand its product portfolio, focusing on the development and market launch of its patented A.I. applications for bone health assessment. The company aims to introduce these new technologies in the U.S., Europe, Asia, and Latin America, targeting a broader market presence. Through these initiatives, Medimaps Group intends to enhance its offerings and address the growing demand for advanced bone health assessment tools.

## Funding rounds

- Series C, Nov 1, 2021, $20M — Swisscom Ventures, Swisscanto, Swiss Entrepreneurs Foundation, Verve Ventures

## Investors

- Swisscom Ventures (https://capitalatlas.ai/funds/swisscom-ventures) — Series C
- Swisscanto (https://capitalatlas.ai/funds/swisscanto) — Series C
- Swiss Entrepreneurs Foundation (https://capitalatlas.ai/funds/swiss-entrepreneurs-foundation) — Series C
- Verve Ventures (https://capitalatlas.ai/funds/verve-ventures) — Series C